Gilead Sciences Inc - Current report filing (8-K)
October 18 2007 - 4:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
October 18, 2007
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
0-19731
|
|
94-3047598
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA
(Address of principal executive offices)
94404
(Zip Code)
(650) 574-3000
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFD 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
SECTION 2 FINANCIAL INFORMATION
Item 2.02
|
Results of Operations and Financial Condition.
|
On October 18,
2007, Gilead Sciences, Inc., a Delaware corporation (the Company), issued a press release announcing its financial results for the quarter ended September 30, 2007. A copy of the press release is filed as Exhibit 99.1 to this report.
Non-GAAP net income, net income per diluted share, research and development (R&D) expenses and selling, general and administrative (SG&A)
expenses for the 2007 periods are presented excluding the impact of stock-based compensation expense and the related methodology for deriving dilutive securities. Non-GAAP net income, net income per diluted share, R&D expenses and SG&A
expenses for the 2006 periods are presented excluding the impact of stock-based compensation expense and the related methodology for deriving dilutive securities, as well as the impact of the purchased in-process R&D charge incurred in
connection with the acquisition of Corus Pharma, Inc. Management believes this non-GAAP information is useful for investors, taken in conjunction with Gileads GAAP financial statements, because management uses such information internally
for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Companys operating results as
reported under United States generally accepted accounting principles.
The information in this Form 8-K and the exhibit attached hereto shall not be
deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01
|
Financial Statements and Exhibits.
|
|
|
|
Exhibit
Number
|
|
Description
|
99.1
|
|
Press Release, issued by Gilead Sciences, Inc. on October 18, 2007
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
GILEAD SCIENCES, INC.
|
(Registrant)
|
|
/s/ John F. Milligan
|
John F. Milligan, Ph.D.
Chief Operating Officer and
Chief Financial Officer
|
Date: October 18, 2007
Exhibit Index
|
|
|
Exhibit
Number
|
|
Description
|
99.1
|
|
Press Release, issued by Gilead Sciences, Inc. on October 18, 2007
|
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024